

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20223> holds various files of this Leiden University dissertation.

**Author:** Spijker, Anne Titia

**Title:** Cortisol exposure, cognition and clinical course of bipolar disorder

**Issue Date:** 2012-12-04



## 2. Glucocorticoid sensitivity in Mood Disorders - Review



**Authors:**

A.T. Spijker, E.F.C. van Rossum

Neuroendocrinology 2012;95:179–186



**Abstract:**

In this review we provide an overview of recent literature on glucocorticoid (GC) sensitivity in mood disorders. Assessing GC sensitivity is often performed by measuring the Cortisol Awakening Rise (CAR), by challenging the Hypothalamic- Pituitary- Adrenal (HPA) -axis using a Dexamethasone Suppression Test (DST) or a Dexamethasone/ Cortisol Releasing Hormone test (DEX/CRH); more recently by measuring cortisol as a retrospective calendar in scalp hair. The main findings in mood disorders are higher mean cortisol levels in hair samples and in the CAR, showing a hyperactivity of the HPA-axis. This is in line with the mild resistance for GCs previously observed in challenge tests during mood episodes. GC sensitivity is partly determined by polymorphisms in the genes encoding receptors and other proteins involved in the regulation of the HPA-axis. We shortly discuss the Glucocorticoid Receptor, as well as the Mineralocorticoid Receptor, the CRH-Receptor 1, and the GR co-chaperone FKBP5. Data clearly indicate genetic changes, along with epigenetic changes which influence the set point and regulation of the HPA-axis. Early trauma, as well as influences in utero, appears to be important. Future research is necessary to further clarify the biological background and consequences of an individual's cortisol exposure in relation to mood.

## Content

1. Introduction
2. Assessment of Glucocorticoid Sensitivity in relation to mood
  - a. The Cortisol Awakening Rise
  - b. Challenging the Hypothalamic- Pituitary- Adrenal (HPA) -axis
  - c. Cortisol in scalp hairs
3. Genetics of HPA-axis: consequences for physical and mental health
  - a. Glucocorticoid Receptor (GR) polymorphisms: physical health
  - b. GR polymorphisms: mental health
  - c. Mineralocorticoid Receptor (MR) polymorphisms
  - d. FKBP5 and Cortisol Releasing Hormone Receptor 1 (CRH-R1) polymorphisms
4. Epigenetics of the HPA- axis: adversity in childhood
5. Conclusive remarks

## 1. Introduction

During daily life, mood is known to be largely influenced by circadian rhythms and stress. An individual's risk to develop a mood disorder can depend on one or a combination of factors including vulnerability, defined by genetics, early life stress, and consequences of life events. The biological stress response has an important function in coping with life events, and differs between individuals with a genetically and epigenetically determined set-point during youth. The key systems in the stress response are regulated by fast adrenergic neurotransmitters (the sympathetic nervous system) and slower glucocorticoid hormones (the Hypothalamic-Pituitary-Adrenal-axis, the HPA-axis), of which cortisol is the main hormone in humans. It is complex to properly measure and assess the functioning HPA-axis in humans. However, it is important to evaluate the role of the stress response in the flexibility of the individual to cope with physical and mental changes in life in order to identify risk factors defining health and disease. In addition, an individual's level of chronic cortisol exposure in brain areas related to affection and cognition, may be very important in mood disorders. Aside from the stress system reactivity, it is also important to mention the consequences of absolute high and low cortisol levels. The consequences of absolute high cortisol levels is best observed in the clinically well known Cushing's syndrome, where cortisol levels are usually extremely high due to exogenous or endogenous causes. These symptoms can vary between physical symptoms, for example weight gain, increase abdominal fat, hyperhidrosis and hirsutism, and psychiatric symptoms, for example manic and depressive episodes, psychosis and anxiety. Also hypocortisolism as seen in Morbus Addison can have serious consequences on mental health, making patients vulnerable to mood disorders and anxiety.

Cortisol is known to exert its effect through two receptors: the Glucocorticoid Receptor (GR) and the Mineralocorticoid Receptor (MR). Both receptors are also present in the brain. The GR is found throughout the brain, with a very high density in the hippocampus, the PreFrontal Cortex (PFC), the paraventricular nucleus of the hypothalamus, the amygdala and the dentate gyrus. The MR is predominantly found in the hippocampus, the PFC and the amygdala (1). The GR is known to be an important regulator during the acute stress response, while both GR and MR are active under basal conditions. Both corticosteroid receptors are co-expressed in the limbic system and it seems obvious that both receptor systems have a balanced function in regulating the stress response (2). FKBP5, a co-chaperone of the GR, also influences GR activity (3). Finally, the Cortisol Releasing Hormone Receptor type 1 (CRHR1) is important in initiating the stress response.

## 2. Assessment of Glucocorticoid Sensitivity in relation to mood

Functional evaluation of the HPA-axis is complex. The HPA-axis is characterized by daily rhythms, seasonal rhythms, and pulsation leading to varying cortisol levels in blood and saliva. The two most common approaches to evaluate HPA-axis functioning are the measurement of basal cortisol levels in response to awakening, as a model for an endogenous stress response; and the measurement of the HPA-axis functioning during challenging conditions, which gives an impression about the reactivity of the stress response itself. This measurement is characterized by negative feedback at the pituitary level on the production of Adrenocorticotrophic hormone (ACTH), and hence by diminished stimulation of the cortisol production in the adrenal glands.

### a. *The Cortisol Awakening Rise*

It is best to collect samples immediately upon waking to evaluate the Cortisol Awakening Rise (CAR), which reflects the natural response to awakening with an increase in cortisol levels of 50-75% within half an hour after awakening (4). Several influences on the CAR are defined by Vreeburg et al., including sleep patterns (duration, awakening time), season of sampling, activities (working day, physical activity) and health indicators (smoking, cardiovascular disease, physical activity) (5). Also psychosocial stressors and job stress have been found to result in higher CARs, whereas exhaustion and burnout resulted in lower CARs (6).

In patients with mood disorders, a higher CAR was observed in both remitted (n=579) and currently depressed (n=701) patients (7). In acutely depressed outpatients cortisol levels were 25% higher compared with healthy controls (8). In addition to this finding, a study among 230 late adolescents revealed that a higher CAR was predictive for developing a Major Depressive Disorder (MDD) within a year after sampling (9). In addition, subjects without a history of depression but with parents diagnosed with MDD had higher CARs, which were equal to the subjects with a current depression (10). It seems that these findings reflect higher basal cortisol levels as a trait phenomenon irrespective of current status.

### b. *Challenging the HPA-axis*

The Dexamethasone Suppression Test (DST) is a neuroendocrine test measuring GR-mediated negative feedback. This test consists of a low dose administration (1 mg or 0.25 mg) of dexamethasone, a synthetical glucocorticoid hormone, at 11 pm and the measurement of cortisol levels the following morning. Due to the negative feedback

action at the pituitary and hypothalamic levels subsequent cortisol levels are suppressed the next day. Non-suppression of cortisol levels after dexamethasone indicates GR resistance. The strength of cortisol suppression reflects the negative feedback mechanism, which is largely variable between but rather stable within individuals (11). The test is very easy, however an important restriction to consider for use in psychiatry is the limited sensitivity in studying MDD (12). In particular in outpatients the sensitivity is low. It was reported that only 12 % of outpatients with non melancholic depression showed non suppression in the DST, while 64% patients with psychotic depression showed non suppression (13). Low percentages of non suppression after 1-2 mg dexamethasone in moderately depressed patients (44%) were found, in contrast with severely depressed psychotic patients and bipolar patients (67-78%) (14). Heuser et al developed the combined DEX/Cortisol Releasing Hormone- test (DEX/CRH- test) as a refinement of the DST (15). This challenge test consists of administration of 1.5 mg dexamethasone at 11:00 pm followed by administration of 100 microgram CRH at 3:00 pm on the next day. Cortisol and ACTH levels are sampled every 15 minutes from 2:00 pm until 6:00 pm. This test was found to be more sensitive for MDD (about 80%), and is even above 90% when the cohort was stratified for age.

However, the DEX/CRH-test is more intrusive for patients, which limits the use in research among large cohorts of outpatients. Zobel et al found that in a cohort of 74 remitted patients, the DEX/CRH test was able to predict relapse of depression within six months (16). In patients with a relapse within 6 months after discharge, there was a 4- to 6-fold increased cortisol response in the DEX/CRH-test just before discharge. In accordance to, Appelhof et al found in a sample of 45 outpatients with remitted major depression that higher cortisol levels in the DEX/CRH test were associated with relapse (17), which was confirmed by Ising et al (18). Rybakowski et al. also stressed that number of episodes was associated with more non-suppression. Bipolar patients in the same study were found to have most non-suppression when compared with healthy controls and unipolar depressed patients in remission. Watson *et al* confirmed that in bipolar patients, cortisol levels in response to the DEX/CRH test are increased, with no difference between a current depressive episode and remission (19).

The issue whether this is a state or trait phenomenon is not yet solved. The studies including healthy family members suggest that hyperactivity of the HPA-axis is not only a reflection of current mood state (20). A new approach to this problem is the scar theory (21), describing long lasting changes in the function of the brain (cognition, biological) following depression, increasing the risk for developing future depressive episodes. The pre-morbid regulated “set-point” of the HPA-axis is thought to be changed through depression by for example epigenetic changes in DNA methylation in depressed suicide victims (22) and children of mothers who were depressed during pregnancy (23). This



scarring process is possibly a structural phenomenon developed during life. In section 4 we will briefly discuss the influence of early life trauma on epigenetic phenomena.

### *c. Cortisol in scalp hairs*

A novel and non-invasive parameter is measuring cortisol in scalp hair. Hair grows with an average of 1 cm per month, and it has been shown that cortisol can be reliably measured in hair (24-26). The use of hair provides the opportunity to measure long term cortisol levels (reflecting mean levels of the past months) in an easy way without limitations caused by the pulsatility and circadian rhythm of cortisol or acute circumstances. Strong correlations of hair cortisol have been observed with tissue effects of cortisol in healthy individuals (e.g. waist circumference), as well as with cortisol exposure in patients with hyper-or hypocortisolism (26). This method has only preliminary been applied in psychiatry. Steudte et al found a decreased cortisol level in patients with generalized anxiety disorder (27). Our group recently found that cortisol levels were increased in patients with BD when having a co-morbid psychiatric diagnosis (28). Interestingly, hair cortisol levels were decreased when patients with BD were also diagnosed with panic disorder. Moreover, we found an association of higher hair cortisol levels with adult onset (older than 30 years) of BD, and impaired executive functioning, compared to patients with puberty onset, normal executive functioning and normal cortisol levels (29).

## **3. Genetics of HPA-axis: consequences for physical and mental health**

### *a. GR polymorphisms: physical health*

There are several known genetic variations in the GR Gene *NR3C1* with consequences for cortisol sensitivity (30). Subtle changes in cortisol signaling leading to relative resistance or hypersensitivity for Glucocorticoids (GCs) can have long term consequences. It is known that these changes can affect metabolic and inflammatory status and body composition. Cognitive performance and mental health can also be influenced by altered HPA-axis regulation.

Haplotype 4 (*Tthllll* + 9 $\beta$ ) and haplotype 5 (*Tthllll* + 9 $\beta$  + ER22/23EK) are both associated with a relative resistance for GCs (31-34). The ER22/23EK polymorphism is associated with a healthy metabolic and inflammatory profile, characterized by lower total cholesterol and low-density lipoprotein cholesterol levels as well as lower fasting insulin concentrations, a better insulin sensitivity and lower C-reactive protein levels (32, 35).

This GR variant is also associated with a beneficial body composition, shown by young male ER22/23EK carriers (taller, stronger and more muscle mass than non-carriers) and female ER22/23EK carriers (tendencies for smaller waist and hip circumferences, lower body weight (33) and protective effect on weight gain during pregnancy (36). These associations of the ER22/23EK polymorphism are in line with a mild GR resistance. The clinical data are supported by in vitro experiments showing reduction of transactivating capacity in transfection experiments and in peripheral blood mononuclear lymphocytes of carriers of this polymorphism (37). In addition the underlying molecular mechanism of the GR gene variant has been revealed (38).

The 9 $\beta$ -polymorphism seems to increase the stability of mRNA of GR- $\beta$ , an alternative splice variant of the GR-gene (31). GR- $\beta$  is thought to exert a dominant negative effect on the active GR- $\alpha$ . The association of the 9 $\beta$  polymorphism and the immune system has been shown by the higher risk of developing rheumatoid arthritis in carriers (31, 39). Patients with Multiple Sclerosis (MS) have been found to have a more aggressive course of disease when they carry at least one allele of haplotype 5 (*TthIII* + 9 $\beta$  + ER22/23EK), which is possibly related with an altered inflammatory state due to GC resistance (40). Interestingly, in 2008 van den Akker et al reported that the 9 $\beta$  polymorphism is related to a more active pro-inflammatory system, and subsequently associated with the risk of cardiovascular disease (41). In line with these findings the Heart and Soul Study showed that the 9 $\beta$  SNP is associated with reduced heart function, partly mediated by low-grade inflammation (42).

Haplotype 2 (*BclI*), haplotype 3 (*TthIII* + *BclI*) and haplotype 6 (N363S) have all been associated with a relative hypersensitivity to GCs and clinical signs of hypersensitivity to cortisol in various tissues (43). Carriers of N363S have in addition to increased cortisol suppression also an increased insulin response in the DST, a tendency towards lower bone mineral density, and increased body mass index (BMI) (33). Although other studies have reported associations with increased BMI, as expected as a result of glucocorticoid hypersensitivity, these findings have not been consistently confirmed (30, 44). The *BclI* polymorphism has been found to be associated with abdominal obesity (33), lower bone mineral density (45) and unhealthy body composition in young boys (46).

### *b. GR polymorphisms: mental health*

Recently we reviewed the GR and MR SNPs in relation to mood disorders (47). The most important findings will be summarized and supplemented by recent progress in this area of research. The ER22/23EK polymorphism has repeatedly been associated with a higher risk on developing a depressive episode (48-50), and a faster response

after antidepressant treatment (48). In the study of Bet et al. an association to this polymorphism and clinically relevant depressive symptoms in an elderly population was only found in combination with childhood adversity, indicating a gene-environment interaction. Recently, attention has been directed to the 9 $\beta$  SNP in relation to mood. In a sample of 245 bipolar patients, we found an association between the 9 $\beta$  polymorphism and reduced risk on (hypo) mania (51). In the aforementioned study of Bet et al. a relationship between this SNP and clinically relevant depressive symptoms, in combination with childhood adversity was found (50). Recently, in a sample of 173 patients with bipolar I depressive episodes, the response to lamotrigine (anti-epileptic medication used in treatment of bipolar depression) in a subgroup of 88 patients was associated with the GR polymorphisms rs258747 and rs6198 (9 $\beta$ ) (52). Finally, in a group of 526 outpatients with coronary heart disease the prevalence of depression was increased with an allele-dosage effect (from 24.4% of the non-carriers to 52.9% of the homozygous 9 $\beta$  carriers) (53). The *BclI* polymorphism is also associated with an increased risk on developing a depressive episode (48, 54-56), as well as with a reduced response after antidepressant treatment (54), which was not confirmed by Lee et al (56). Remarkably, in the latter study, it was found that in the Korean population there were no carriers of ER22/23EK and N363S. This is consistent with other reports in Asian populations (57).

### c. *MR polymorphisms*

In figure 1, 2 SNPs in the MR Gene and 3 haplotypes are shown. The V allele in the MRI180V SNP is associated with higher cortisol levels in saliva and plasma in healthy subjects performing the Trier Social Stress Test (a validated psychological procedure inducing acute stress under laboratory circumstances, allowing evaluation of biological measurements of differences in stress levels between individuals). In vitro testing, using transactivational assays, this I180V variant was shown to have a slight loss of function using cortisol as a ligand (58). This SNP was associated with higher frequency of depressive symptoms in an elderly cohort (participants aged > 85 years) (59) and with neuroticism in depressed patients (60). Another MR SNP, the -2G/C variant also affects the transactivational capacity of the MR in vitro in response to cortisol. Both SNPs modified cortisol suppression in a DST (0.25 mg DEX) in a sex specific manner (61).

### d. *FKBP5 and CRH-R1 polymorphisms*

An important co-chaperone protein functionally interacting with the GR is FK506 binding protein 5, better known as FKBP5, a member of the immunophilin protein family. Genetic

variations in the FKBP5 gene lead to increased intracellular FKBP5 protein expression, which in turn leads to adaptation of the GR function. Healthy subjects carrying these SNPs show GR resistance and diminished negative feedback of the HPA-axis. Carriers of these variations have been found to be overrepresented in patients with mood disorders (MDD and BD) and post-traumatic stress disorder (62), as well as respond faster to antidepressant treatment (63). Another gene, which is a key factor in the HPA-axis is the CRH1- receptor (CRH-R1). This receptor has been considered as a mediator in initiating the stress response. The CRH-R1 is located in the paraventricular nucleus (PVN) of the hypothalamus, the hippocampus as well as widely distributed beyond the hypothalamus. It interacts with a wide range of neurotransmitters, for example, influences the activity of the 5-HT<sub>2A/C</sub> receptor (64, 65). Several SNPs in the CRH-R1 gene have been recently identified and explored in relation with mood disorders. Liu et al found an over-representation of rs242939 in patients with major depression compared to healthy controls (66). They also found that rs242941 carriers with major depression and high levels of anxiety responded faster after treatment with fluoxetine in 127 Han Chinese patients (67). This was not confirmed by Dong et al in a population of 536 unrelated Mexican Americans from Los Angeles (68). In male suicide attempters a relation between illness severity and a haplotype of the CRHR1 has been found (69), as well as in their offspring with CRH-R1 haplotypes, who were found to score higher on the Beck Depression Inventory, which was found in the same study.

Interestingly, these SNPs in the CRHR1 gene are also studied in relation with the environment and with other genes. Experiencing childhood abuse leads to a higher risk for developing a lifetime depressive episode specifically in carriers of polymorphisms of the CRH-R1 *in combination with* the short serotonin transporter gene 5-HTTLPR (70). In parallel, Bradley et al found an interaction between SNPs in the CRHR1 gene and childhood abuse as predictor for depressive episodes (71). In one cohort of more than 1,000 female participants, Polanczyk et al found that carriers of a haplotype formed by rs7209436, rs110402, and rs242924 who were abused during childhood as measured by the Childhood Trauma Questionnaire (CTQ) are protected against depression in adulthood (72). This was not replicated in another cohort described in the same study, where childhood abuse was not measured by the CTQ.

A recent review by Binder and Nemeroff extensively summarized the relation between genetics of the CRH system in relation with psychopathology (64).

#### 4. Epigenetics of the HPA-axis: adversity in childhood

The influence of genetic variations in the DNA sequences of HPA-axis related genes on mood disorders is clear, but may only be one brick in the building of our understanding of mood disorders. Of all other influences, it is important to mention epigenetic changes in regulating the “set-point” of the HPA-axis. Epigenetic changes comprise changes in gene expression which remain stable during cell divisions, but do not affect the DNA sequence itself. Epigenetic changes are heritable and could be caused by changes such as those found in DNA methylation, the modeling of chromatin and the de-acetylation of histones in the DNA.

Several circumstances can lead to epigenetic changes, for example intra-uterine influences and changes in early youth due to childhood adversity. A well-known example of intra-uterine effects on health in adulthood is the Dutch Famine Birth Cohort study. Children of the women who were pregnant during the famine in World-War II scored lower in mental health, and this effect was repeated in their children’s children, suggesting an epigenetic effect (73). However, there was no relation found with changes in HPA-axis regulation (74). Other studies emphasize the importance of regulation of the HPA-axis in utero. Raised GC concentrations during pregnancy are associated with lower birth weight and later during childhood and adulthood with an increased cortisol response during HPA-axis activation (75). As a consequence these patients are at higher risk to develop obesity and/or diabetes. Yehuda et al report that women who were pregnant during the World Trade Centre Attack and developed Post Traumatic Stress Disorder had lower salivary cortisol levels, as did their 1-yr old offspring, suggesting they had already developed a risk factor for PTSD in later life (76). Animal studies show that prenatal stressed offspring developed hyper activation of the HPA-axis through epigenetic programming, and develop high anxiety levels and depression-like behavior (77, 78).

In early childhood the regulation of the HPA-axis is further developed. Early life trauma could have devastating consequences for the HPA-axis “set-point”. In a recent review, the relation between early life trauma and the HPA-axis is characterized by hypocortisolism and an attenuated cortisol response during acute stress (79), which suggests a dysregulation of the negative feedback mechanism in the HPA-axis. This diminished stress response is continued throughout life and tends to worsen with ageing (80). Animal studies have shown that mouse pups that have been separated for several days from their mothers, have an increased GR expression in frontal cortical and hippocampal areas during the separation. After the separation they showed a diminished GR expression (81). In humans this was recently confirmed by McGowan et al, showing that suicide victims with a history of childhood abuse had decreased GR mRNA levels in the hippocampus, as well as increased cytosine methylation of the GR (82). Secure attachment is a central theme

in the work of Bowlby and Ainsworth. The “strange situation” is a classic test, comprising a short separation between mother and child. After reunion the response of the child towards the mother is categorized in attachment styles, reflecting the involvement or neglect/abuse of the mother for her child (83). Neglect by the mother is devastating for the development of a secure attachment style of the child, with definite changes (e.g. alterations of methylation pattern of the GR) for the rest of its life.

## 5. Conclusive remarks

In conclusion, while accumulating evidence indicates that alterations in the HPA-axis are important biological factors in mood disorders, the exact pathophysiological mechanisms are at present not completely understood. This is partly due to the difficulties in assessing the HPA-axis. One of the promising future techniques could be the assessment of the long term cortisol levels through analysis of scalp hairs. The “set-point” of the HPA-axis is influenced by genetic changes in the GR gene, MR gene, CRH-R1 gene and FKBP5 gene, as well as polymorphisms in other genes involved in cortisol signaling. These changes have been associated with mood disturbances. During life this set-point is further defined by epigenetic changes due to intrauterine influences and/or childhood adversity. Finally, during life this set-point could be influenced by mood episodes. As a result, hyperactivity of the HPA-axis may increase the vulnerability for future mood episodes.

Future research should focus on new tools in order to obtain a clear indication of an individual’s cortisol status. This may provide better opportunities to understand possible causal relationships between cortisol exposure (in the brain) and mood disorders which may yield new treatment strategies.

## References

1. Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. *J Psychiatr Res.* 2000; 34:383-92.
2. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. *NatRevNeurosci.* 2005; 6:463-75.
3. Pratt WB TD. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev.* 1997; 18:306-60.
4. Wust S, Wolf J, Hellhammer DH, Federenko I, Schommer N, Kirschbaum C. The cortisol awakening response - normal values and confounds. *Noise Health.* 2000; 2:79-88.
5. Vreeburg SA, Kruijtzter BP, van Pelt J, van Dyck R, DeRijk RH, Hoogendijk WJG, et al. Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. *Psychoneuroendocrinology.* 2009; 34:1109-20.
6. Chida Y, Steptoe A. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. *Biol Psychol.* 2009; 80:265-78.
7. Vreeburg SA, Hoogendijk WJ, van PJ, DeRijk RH, Verhagen JC, van DR, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. *ArchGenPsychiatry.* 2009; 66:617-26.
8. Bhagwagar Z, Hafizi S, Cowen PJ. Increased salivary cortisol after waking in depression. *Psychopharmacology (Berl).* 2005; 182:54-7.
9. Adam EK, Doane LD, Zinbarg RE, Mineka S, Craske MG, Griffith JW. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. *Psychoneuroendocrinology.* 2010; 35:921-31.
10. Vreeburg SAH, Catharina A.; Hoogendijk, Witte J. G.; van Dyck, Richard ; Zitman, Frans G. ; Ormel, Johan ; Penninx, Brenda W. J. H. Parental history of depression or anxiety and the cortisol awakening response. *British Journal of Psychiatry* September. 2010; 197:180-5.
11. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, et al. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. *J Clin Endocrinol Metab.* 1998; 83:47-54.
12. Craig Nelson J, Davis JM. DST studies in psychotic depression: A meta-analysis. *Am J Psychiatry.* 1997; 154 (11):1497-503.

13. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. *Am J Psychiatry*. 1997; 154:1497-503.
14. Arana GW, Baldessarini RJ, Ornstein M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. *Archives of General Psychiatry*. 1985; 42:1193-204.
15. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *JPsychiatrRes*. 1994; 28:341-56.
16. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. *JPsychiatrRes*. 2001; 35:83-94.
17. Appelhof BC, Huyser J, Verweij M, Brouwer JP, van Dyck R, Fliers E, et al. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). *Biol Psychiatry*. 2006; 59:696-701.
18. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? *Biol Psychiatry*. 2007; 62:47-54.
19. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. *BrJPsychiatry*. 2004; 184:496-502.
20. Ellenbogen MA, Santo JB, Linnen AM, Walker CD, Hodgins S. High cortisol levels in the offspring of parents with bipolar disorder during two weeks of daily sampling. *Bipolar Disord*. 2010; 12:77-86.
21. Wichers M, Geschwind N, van Os J, Peeters F. Scars in depression: is a conceptual shift necessary to solve the puzzle? *Psychol Med*. 2010; 40:359-65.
22. Poulter MO, Du L, Weaver ICG, Palkovits M, Faludi G, Merali Z, et al. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. *Biol Psychiatry*. 2008; 64:645-52.
23. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. *Epigenetics: Official Journal of the DNA Methylation Society*. 2008; 3:97-106.
24. Van Uum SH, Sauve B, Fraser LA, Morley-Forster P, Paul TL, Koren G. Elevated content of cortisol in hair of patients with severe chronic pain: a novel biomarker for stress. *Stress*. 2008; 11:483-8.



25. Kirschbaum C, Tietze A, Skoluda N, Dettenborn L. Hair as a retrospective calendar of cortisol production-Increased cortisol incorporation into hair in the third trimester of pregnancy. *Psychoneuroendocrinology*. 2009; 34:32-7.
26. Manenshijn L, Koper JW, Lamberts SWJ, van Rossum EFC. Evaluation of a method to measure long term cortisol levels. *Steroids*. 2011; 76:1032-6.
27. Steudte S, Dettenborn L, Klumbies E, Foley P, Beesdo-Baum K,, C. K. Decreased hair cortisol concentrations in generalised anxiety disorder. *Psychiatry Res*. 2010; Epub ahead of print.
28. Manenshijn L, Spijker AT, Koper JW, Jetten AM, Giltay EJ, Hoencamp E, et al. Long-term cortisol in bipolar disorder: Associations with age of onset and psychiatric co-morbidity. *Psychoneuroendocrinology*. 2012.
29. Spijker AT ML, Koenders M, Jetten AM, Haffmans J, Hoencamp E, van Rossum EFC Cortisol levels in scalp hair in relation to age of onset and cognition in patients with Bipolar Disorder. *Tijdschr v Psychiatrie*. 2011; Suppl. 1:330.
30. Manenshijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. *Ann N Y Acad Sci*. 2009; 1179:179-98.
31. Derijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. *J Rheumatol*. 2001; 28:2383-8.
32. van Rossum EF, Koper JW, Huizenga NA, Uitterlinden AG, Janssen JA, Brinkmann AO, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. *Diabetes*. 2002; 51:3128-34.
33. van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. *Recent ProgHormRes*. 2004; 59:333-57.
34. van den Akker EL, Russcher H, van Rossum EF, Brinkmann AO, de Jong FH, Hokken A, et al. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. *JClinEndocrinolMetab*. 2006; 91:2800-3.
35. van Rossum EF, Feelders RA, van den Beld AW, Uitterlinden AG, Janssen JA, Ester W, et al. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. *Am J Med*. 2004; 117:158-62.
36. Bertalan R, Patocs A, Boyle B, Rigo J, Racz K. The protective effect of the ER22/23EK polymorphism against an excessive weight gain during pregnancy. *Gynecol Endocrinol*. 2009; 25:379-82.

37. Russcher H, Smit P, van den Akker EL, van Rossum EF, Brinkmann AO, de Jong FH, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. *J Clin Endocrinol Metab.* 2005; 90:5804-10.
38. Russcher H, van Rossum EF, de Jong FH, Brinkmann AO, Lamberts SW, Koper JW. Increased expression of the glucocorticoid receptor-A translational isoform as a result of the ER22/23EK polymorphism. *MolEndocrinol.* 2005; 19:1687-96.
39. van Oosten MJ, Dolhain RJ, Koper JW, van Rossum EF, Emonts M, Han KH, et al. Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. *Arthritis Res Ther.* 2010; 12:R159.
40. van Winsen LM, Manenschijn L, van Rossum EF, Crusius JB, Koper JW, Polman CH, et al. A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis. *J Clin Endocrinol Metab.* 2009; 94:2110-4.
41. van den Akker EL, Koper JW, van Rossum EF, Dekker MJ, Russcher H, de Jong FH, et al. Glucocorticoid receptor gene and risk of cardiovascular disease. *Arch Intern Med.* 2008; 168:33-9.
42. Otte C, Wust S, Zhao S, Pawlikowska L, Kwok P-Y, Whooley MA. Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. *J Clin Endocrinol Metab.* 2010; 95:2885-91.
43. van Rossum EF, Koper JW, van den Beld AW, Uitterlinden AG, Arp P, Ester W, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. *ClinEndocrinol(Oxf).* 2003; 59:585-92.
44. Rosmond R, Holm G. A 5-year follow-up study of 3 polymorphisms in the human glucocorticoid receptor gene in relation to obesity, hypertension, and diabetes. *J Cardiometab Syndr.* 2008; 3:132-5.
45. Szappanos A, Patocs A, Toke J, Boyle B, Sereg M, Majnik J, et al. BclI polymorphism of the glucocorticoid receptor gene is associated with decreased bone mineral density in patients with endogenous hypercortisolism. *Clin Endocrinol (Oxf).* 2009; 71:636-43.
46. Voorhoeve PG, van den Akker EL, van Rossum EF, Koper JW, van Mechelen W, Lamberts SW, et al. Glucocorticoid receptor gene variant is associated with increased body fatness in youngsters. *Clin Endocrinol (Oxf).* 2009; 71:518-23.
47. Spijker AT, van Rossum EF. Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. *Ann N Y Acad Sci.* 2009; 1179:199-215.
48. van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, et al. Polymorphisms of the glucocorticoid receptor gene and major depression. *Biol Psychiatry.* 2006; 59:681-8.

49. Van West D, Van Den EF, Del-Favero J, Souery D, Norrback KF, Van DC, et al. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. *Neuropsychopharmacology*. 2006; 31:620-7.
50. Bet PM, Penninx BWJH, Bochdanovits Z, Uitterlinden A, x00E, Beekman ATF, et al. Glucocorticoid receptor gene polymorphisms and childhood adversity are associated with depression: New evidence for a gene-environment interaction. *Am J Med Genet B Neuropsychiatr Genet*. 2009; 150B:660-9.
51. Spijker AT, van Rossum EF, Hoencamp E, DeRijk RH, Haffmans J, Blom M, et al. Functional polymorphism of the glucocorticoid receptor gene associates with mania and hypomania in bipolar disorder. *Bipolar Disord*. 2009; 11:95-101.
52. Perlis RH, Adams DH, Fijal B, Sutton VK, Farmen M, Breier A, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. *J Clin Psychiatry*. 2010; 71:599-605.
53. Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA. Glucocorticoid receptor gene and depression in patients with coronary heart disease: The Heart and Soul Study-2009 Curt Richter Award Winner. *Psychoneuroendocrinology*. 2009; 34:1574-81.
54. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. *Psychoneuroendocrinology*. 2006; 31:1154-63.
55. Krishnamurthy P, Romagni P, Torvik S, Gold PW, Charney DS, tera-Wadleigh S, et al. Glucocorticoid receptor gene polymorphisms in premenopausal women with major depression. *HormMetab Res*. 2008; 40:194-8.
56. Lee HY, Kang RH, Han SW, Paik JW, Chang HS, Jeong YJ, et al. Association of glucocorticoid receptor polymorphisms with the susceptibility to major depressive disorder and treatment responses in Korean depressive patients. *Acta Neuropsychiatrica*. 2009; 21:11-7.
57. Duan Z-X, Gu W, Du D-y, Hu P, Jiang D-p, Zhu P-F, et al. Distributions of glucocorticoid receptor gene polymorphisms in a Chinese Han population and associations with outcome after major trauma. *Injury*. 2009; 40:479-83.
58. DeRijk RH WS, Meijer OC, Zennaro MC, Federenko IS, Hellhammer DH,, Giacchetti G VE, Zitman FG, de Kloet ER. . A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. *J Clin Endocrinol Metab*. 2006; 12:5083-9.
59. Kuningas M, de Rijk RH, Westendorp RG, Jolles J, Slagboom PE, van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. *Neuropsychopharmacology*. 2007; 32:1295-301.
60. DeRijk RH, de Kloet ER, Zitman FG, van Leeuwen N. Mineralocorticoid receptor gene variants as determinants of HPA axis regulation and behavior. *Endocr Dev*. 2011; 20:137-48.

61. van Leeuwen N, Kumsta R, Entringer S, de Kloet ER, Zitman FG, DeRijk RH, et al. Functional mineralocorticoid receptor (MR) gene variation influences the cortisol awakening response after dexamethasone. *Psychoneuroendocrinology*. 2010; 35:339-49.
62. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. *Psychoneuroendocrinology*. 2009; 34 Suppl 1:S186-95.
63. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. *Nature Genetics*. 2004; 36:1319-25.
64. Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. *Mol Psychiatry*. 2010; 15:574-88.
65. Magalhaes AC, Holmes KD, Dale LB, Combs-Agrar L, Lee D, Yadav PN, et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT<sub>2</sub> receptor signaling. *Nat Neurosci*. 2010; 13:622-9.
66. Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. *Neuroscience Letters*. 2006; 404:358-62.
67. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. *Neuroscience Letters*. 2007; 414:155-8.
68. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. *Mol Psychiatry*. 2009; 14:1105-18.
69. Wasserman D, Wasserman J, Rozanov V, Sokolowski M. Depression in suicidal males: genetic risk variants in the CRHR1 gene. *Genes, Brain, & Behavior*. 2009; 8:72-9.
70. Ressler KJ, Bradley B, Mercer KB, Deveau TC, Smith AK, Gillespie CF, et al. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. *Am J Med Genet*. 2010; Part B, *Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics*. 153B:812-24.
71. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. *Arch Gen Psychiatry*. 2008; 65:190-200.
72. Polanczyk G, Caspi A, Williams B, Price TS, Danese A, Sugden K, et al. Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. *Archives of General Psychiatry*. 2009; 66:978-85.

73. Stein AD, Pierik FH, Verrips GHW, Susser ES, Lumey LH. Maternal exposure to the Dutch famine before conception and during pregnancy: quality of life and depressive symptoms in adult offspring. *Epidemiology*. 2009; 20:909-15.
74. de Rooij SR, Painter RC, Phillips DIW, Osmond C, Tanck MWT, Bossuyt PMM, et al. Cortisol responses to psychological stress in adults after prenatal exposure to the Dutch famine. *Psychoneuroendocrinology*. 2006; 31:1257-65.
75. Reynolds RM. Corticosteroid-mediated programming and the pathogenesis of obesity and diabetes. *J Steroid Biochem Mol Biol*. 2010; 122:3-9.
76. Yehuda R, Engel SM, Brand SR, Seckl J, Marcus SM, Berkowitz GS. Transgenerational effects of posttraumatic stress disorder in babies of mothers exposed to the World Trade Center attacks during pregnancy. *J Clin Endocrinol Metab*. 2005; 90:4115-8.
77. Abe H, Hidaka N, Kawagoe C, Odagiri K, Watanabe Y, Ikeda T, et al. Prenatal psychological stress causes higher emotionality, depression-like behavior, and elevated activity in the hypothalamo-pituitary-adrenal axis. *Neuroscience Research*. 2007; 59:145-51.
78. Darnaudery M, Maccari S. Epigenetic programming of the stress response in male and female rats by prenatal restraint stress. *Brain Research Reviews*. 2008; 57:571-85.
79. Yehuda R, Flory JD, Pratchett LC, Buxbaum J, Ising M, Holsboer F. Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. *Psychopharmacology (Berl)*. 2010; 212:405-17.
80. Carpenter LL, Tyrka AR, Ross NS, Khoury L, Anderson GM, Price LH. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. *Biol Psychiatry*. 2009; 66:69-75.
81. Navailles S, Zimnisky R, Schmauss C. Expression of glucocorticoid receptor and early growth response gene 1 during postnatal development of two inbred strains of mice exposed to early life stress. *Dev Neurosci*. 2010; 32:139-48.
82. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. [see comment]. *Nat Neurosci*. 2009; 12:342-8.
83. Bretherton I. The origins of attachment theory: John Bowlby and Mary Ainsworth. *Developmental Psychology*. 1992; 28:759-75.